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Abstract
Background: Type II diabetes mellitus (DM II) and coronary artery disease (CAD) are widely understood
to be intimately intertwined disease processes. Today, coronary artery disease is the leading cause of
morbidity and mortality worldwide, and the prevalence of diabetes is reaching epidemic proportions. New
therapies for the management type II DM utilizing incretin mimetics including Glucagon like peptide
(GLP-1) receptor agonists are revolutionizing the current management of DM II. The purpose of this study
was to attempt to elucidate whether GLP-1 infusions improve cardiac markers in setting of acute myocardial
infarction (AMI) in humans.
Methods: An exhaustive search of Medline-OVID, CINAHL, EBMR Multifile, and Web of Science using the
keywords: GLP-1, exenatide, liraglutide, myocardial infarction, myocardial ischemia, cardioprotection,
angioplasty, percutaneous coronary intervention (PCI), ST-elevation myocardial infarction (STEMI), and
non-ST-elevation myocardial infarction (NSTEMI). All bibliographies were screened for relevant articles. All
relevant articles were assessed for quality using GRADE.
Results: Three studies met inclusion criteria and included in this systematic review. A randomized, double-
blinded, placebo-controlled trial of 172 ST-elevation myocardial infarction (STEMI) patients revealed a 15%
larger myocardial salvage index and a 23% smaller final infarct size in the treatment group. A post-hoc analysis
of this data investigating system delay demonstrated no difference between groups with delay >132 minutes.
The final study was a non-randomized pilot study of 21 AMI patients demonstrated improved left ventricular
ejection fraction (LVEF) in the GLP-1–treated group.
Conclusion: Longer duration GLP-1 infusions have been shown to improve LVEF in AMI, a finding that is
more pronounced in patients with clinically severe disease or patients under cardiovascular stress. GLP-1
infusions also increase myocardial salvage and decrease final infarct size. The data is suggestive that GLP-1
infusions have a more profound effect on larger infarcts. There is an upper limit to the timing of GLP-1
administration,which appears to beFinally, GLP-1 infusions also appear to decrease morbidity and mortality
themselves, as evidenced by the reduction of in-hospital mortality and length of hospital stay in AMI patients
undergoing PCI.
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Abstract 
Background: Type II diabetes mellitus (DM II) and coronary artery disease (CAD) are 
widely understood to be intimately intertwined disease processes. Today, coronary artery 
disease is the leading cause of morbidity and mortality worldwide, and the prevalence of 
diabetes is reaching epidemic proportions. New therapies for the management type II DM 
utilizing incretin mimetics including Glucagon like peptide (GLP-1) receptor agonists are 
revolutionizing the current management of DM II. The purpose of this study was to 
attempt to elucidate whether GLP-1 infusions improve cardiac markers in setting of acute 
myocardial infarction (AMI) in humans. 
Methods: An exhaustive search of Medline-OVID, CINAHL, EBMR Multifile, and Web 
of Science using the keywords: GLP-1, exenatide, liraglutide, myocardial infarction, 
myocardial ischemia, cardioprotection, angioplasty, percutaneous coronary intervention 
(PCI), ST-elevation myocardial infarction (STEMI), and non-ST-elevation myocardial 
infarction (NSTEMI). All bibliographies were screened for relevant articles. All relevant 
articles were assessed for quality using GRADE.   
 
Results: Three studies met inclusion criteria and included in this systematic review. A 
randomized, double-blinded, placebo-controlled trial of 172 ST-elevation myocardial 
infarction (STEMI) patients revealed a 15% larger myocardial salvage index and a 23% 
smaller final infarct size in the treatment group. A post-hoc analysis of this data 
investigating system delay demonstrated no difference between groups with delay >132 
minutes. The final study was a non-randomized pilot study of 21 AMI patients 
demonstrated improved left ventricular ejection fraction (LVEF) in the GLP-1–treated 
group. 
 
Conclusion: Longer duration GLP-1 infusions have been shown to improve LVEF in 
AMI, a finding that is more pronounced in patients with clinically severe disease or 
patients under cardiovascular stress. GLP-1 infusions also increase myocardial salvage 
and decrease final infarct size. The data is suggestive that GLP-1 infusions have a more 
profound effect on larger infarcts. There is an upper limit to the timing of GLP-1 
administration,which appears to be <132 minutes. Finally, GLP-1 infusions also appear 
to decrease morbidity and mortality themselves, as evidenced by the reduction of in-
hospital mortality and length of hospital stay in AMI patients undergoing PCI.  
 
Keywords: GLP-1, exenatide, liraglutide, myocardial infarction, myocardial ischemia, 
cardioprotection, angioplasty, PCI, STEMI, NSTEMI 
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GLP-1 Infusions in the setting of Acute Myocardial Infarction Improve Myocardial 
Function and Reduce Morbidity and Mortality 
 
BACKGROUND 
Type II diabetes (DM II) and coronary artery disease (CAD) are widely 
understood to be intimately intertwined disease processes. Today, CAD is the leading 
cause of morbidity and mortality worldwide, and the prevalence of diabetes is reaching 
epidemic proportions. The community-based Framingham Heart Study1 reports the 
incidence of DM II has doubled over the last 30 years, and the worldwide prevalence of 
diabetes is projected to increase from 135 million in 1995 to 300 million in 2025.2 A 
retrospective study by Hu et al,3 found that female patients who were diagnosed with DM 
II over the course of a 20-year study were 3.71 times more likely to suffer an adverse 
cardiac event, and those women who already carried the diagnosis prior to entering the 
study were 5 times more likely to have an adverse cardiac event. Norhammar et al,4 
investigated the glucose metabolism in patients with acute myocardial infarction (AMI) 
and found that of those patients who suffer an AMI without a current diagnosis of DM II, 
31% will be discharged with the diagnosis of DM II, and 35% will be discharged with 
impaired glucose tolerance. This indicates that 2/3 of patients who suffer an AMI have 
some aberration of their glucose metabolism. Additionally, those patients with 
hyperglycemia have increased mortality post-myocardial infarction (MI). Bolk et al,5 
found that the 1-year mortality rate following AMI is 22% in patients with glucose levels 
>200mg/dL upon admission, and just 6% for patients with a blood glucose level of  
<101mg/dL. These studies1-5 all point to a strong and very clinically relevant relationship 
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between CAD and diabetes, and the need to improve management and reduce risk of 
adverse cardiac events.  
New therapies for the management DM II utilizing incretin mimetics including 
glucogon-like-peptide-1 (GLP-1) receptor agonists (liraglutide and exenatide) and 
dipeptidyl-peptidase-4 (DPP-4) inhibitors (the ‘gliptins) are revolutionizing the current 
management of DM II and have shown great promise of cardioprotective effects. GLP-1 
is a gut-derived hormone that is secreted in response to oral ingestion of glucose. 
Endogenous GLP-1 has a half-life of 1-2 minutes before being broken down quickly by 
the enzyme DPP-4. In contrast, GLP-1 receptor agonists are resistant to degradation by 
DPP-4 and therefore have a much longer half-life providing a much larger therapeutic 
window. GLP-1 and GLP-1 receptor agonists inhibit glucagon release and have an 
insulinotropic and insulinomimetic effects that are dependent on plasma glucose levels, 
thus GLP-1 receptor agonists control plasma glucose levels with minimal risk of inducing 
hypoglycemia. This is important to note because multiple studies have shown 
hyperglycemia to be an independent risk factor associated with poor outcomes in the 
setting of AMI.6,7 While, paradoxically the large sample ACCORD8 and VADT9 studies 
reported that hypoglycemia additionally increases the risk of cardiovascular events.  
Taken together, these characteristics suggest GLP-1 receptor agonists are ideal for 
the pharmacological management of DM II by helping to maintain euglycemia and 
consequently reducing cardiovascular risk. In addition to a very favorable glycemic 
profile, GLP-1 receptor agonists have also been found to have multiple extra-glycemic 
effects including: promotion beta cell proliferation and prevention beta cell apoptosis, 
slowing gastric emptying, increasing satiety centrally, promoting weight loss, improving 
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endothelial function, decreasing systolic BP, and improving lipid profile. Many of these 
effects portend an additional reduction in cardiovascular morbidity and mortality. Best et 
al10 concluded in retrospective epidemiological study of 21 754 DM II patients that 
patients treated with the GLP-1 receptor agonist exenatide twice daily were 19% less 
likely to have a cardiovascular event than 361 771 DM II patients treated with other 
glucose lowering agents.  
In addition to cardiovascular risk reduction, GLP-1 and GLP-1 receptor agonists 
have shown direct cardioprotective effects in the reduction of final infarct size and 
protection from oxidative stress and reperfusion injury in AMI animal models.11,12 Bose 
et al11 was able to reproduce these cardioprotective effects in both in-vivo and in-vitro 
studies of GLP-1. In both arms of the study GLP-1 was shown to reduce the final of 
infarct size in rat hearts. The in-vivo model, showed a 20% reduction in the final infarct 
size compared to the control group. The in-vitro study was suggestive that GLP-1 has a 
direct cardioprotective effect that is independent of improved glycemic control via 
insulin, as the study was performed in the absence of circulating insulin. Additionally, 
Bose et al11 may have provided the potential anti-apoptotic cellular pathway of GLP-1 via 
cAMP and G-protein activation of the PI3k enzyme to abolish the effects of BAD 
peptide. BAD is the cardiac myocytes pro-apoptotic member of the Bcl-2 family.  
In study conducted in the porcine model, Timmers et al12 reported a 40% 
reduction in final infarct size following 75 minute total occlusion of the Left circumflex 
artery in pigs treated with exenatide versus placebo. The authors also noted that the left 
ventricular ejection fraction (LVEF) was significantly higher in the exenatide group as 
well.12  
 9 
As previously discussed, GLP-1 receptor agonists are being utilized with 
increasing frequency to improve the management of DM II, and a new role of 
cardioprotection for GLP-1 receptor agonists has shown great promise in animal models 
of AMI. The purpose of this review was to attempt to elucidate whether GLP-1/GLP-1 
receptor agonist infusions improve cardiac markers in setting of AMI in the human 
model. 
 
METHODS  
An exhaustive search was conducted using Medline-OVID, CINAHL, EBMR 
Multifile, Web of Science, and NIH clinical trials website using the keywords: GLP-1, 
incretins, exenatide, liraglutide, myocardial infarction, myocardial ischemia, myocardial 
stunning, reperfusion injury, diabetes, cardioprotection, angioplasty, percutaneous 
coronary intervention (PCI), ST-elevation myocardial infarction (STEMI), Non-ST-
elevation myocardial infarction (NSTEMI), and troponin. All bibliographies of papers 
obtained through this search were screened for additional relevant articles. The inclusion 
criteria was comprised of studies investigating the cardioprotective effects of GLP-1 in 
diabetic and non-diabetic patients undergoing cardiac revascularization in the setting of 
AMI using cardiac markers such as LVEF, myocardial salvage index, infarct size, and 
wall motion. Excluded were animal studies, studies whose primary endpoints were other 
than those outlined above, studies conducted on elective procedures, studies utilizing 
other cardioprotective measures (including ischemic post-conditioning, cyclosporine A, 
and remote conditioning). All relevant articles were assessed for quality using GRADE.13   
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RESULTS 
The initial result of the search yielded 13 articles for review from this search 2 
articles met inclusion criteria. Subsequent searches using combinations of the key terms 
outlined previously yielded 3 more articles that met inclusion criteria. Another article was 
found through review of pertinent bibliographies. This resulted in a total of 6 relevant 
randomized controlled trials. A more detailed screening of these articles revealed only 3 
met criteria of GLP-1 receptor agonists in the setting of AMI (see Table 1). Lastly, a 
search of the NIH clinical trials website revealed there are 3 current or on-going clinical 
trials involving GLP-1 receptor agonist and cardiac markers. 
 
Nikolaidis, et al 
 This paper described the results of a small (n=21), single center, non-randomized, 
pilot study14 designed to evaluate the safety and clinical efficacy of recombinant GLP-1 
(7-36) amide (rGLP-1) in high-risk patients with an AMI and physical exam evidence of 
left ventricle (LV) dysfunction. This study investigated whether a continuous 72-hour 
infusion of rGLP-1 improved ventricular function in the early post-myocardial infarction 
period in patients with Killip class II-IV after successful reperfusion. The Killip 
classification is a system used for risk stratification in AMI using physical exam signs of 
left ventricular dysfunction or heart failure (see Table 2). Patients were excluded from the 
study if they had coronary anatomy warranting coronary artery bypass graft (CABG), 
required hemodialysis (HD), had malignancy, HIV, or CNS disorders, had CPR >30 min, 
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had diabetic ketoacidosis (DKA), or symptomatic hypoglycemia of <60mg/dL.14 
The treatment and control groups were not strictly equivalent. The authors14 
reported the rGLP-1 group tended to be younger, with fewer women, had higher peaks of 
CPK, and a higher prevalence of multivessel disease. However, both treatment and 
control groups had a mean Killip class of III, 3.0±0.1 and 3.1±0.2 respectively. 
Additionally, LV volumes, global and regional indexes, and blood pressures were similar 
between the groups. The authors14 also reported that time of symptom onset, and time to 
reperfusion was also comparable between groups. In terms of treatment, both groups 
received standard post-MI therapy after primary angioplasty, including aspirin, plavix, 
heparin, glycoprotein IIb/IIIa, beta-blockade, ACE inhibitor, and statin.14   
Evaluation of LV function was performed by echocardiography within 2 hours of 
successful angioplasty. After the baseline echocardiography, 72-hour infusion of rGLP-1 
at 1.5pmol/kg/min was initiated. Plasma GLP-1 levels throughout the 72-hour infusion 
were 168±21pmol/L versus 62±11pmol/L, in the treatment and control groups 
respectively. Assessment of LV function by echocardiograph and was repeated within 6-
12 hours after completion of rGLP-1 infusion. The echocardiograph reader was blinded 
to the treatment.14  
Global LVEF post-infusion improved from 29±2% to 39±2% (p<0.01) in the 
rGLP-1–treated patients. This effect was not seen in the control group as Global LVEF 
post-infusion did not improve substantially from 28±2% to 29±2% (no p value reported). 
Regional wall motion score index (WMSI) was reported to be significantly decreased by 
-21±2% (p<0.001) in the rGLP-1–treated group. Again, the change -4±4% reported in the 
control group was not significant. Global WMSI also improved -15±3%, (p<0.001) in 
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rGLP-1–treated patients, but not in the control group 0±3%.14 
The authors14 reported that rGLP-1 infusion had no effect on left ventricular end 
diastolic volume (LVEDV) 91±9 mL to 90±6. However, improvement was noted left 
ventricular end systolic volume (LVESV) which changed from 64±7 mL to 55±5, 
(p<0.01), and therefore stroke volume (SV) was also improved from 26±2 mL to 35±2, 
(p<0.02). There was no evidence of significant change in the control group. Benefits of 
rGLP-1 on global and regional contractile functions were evident in both diabetic and 
non-diabetic patients, as well as patients with anterior and non-anterior infarcts. What’s 
more, follow-up echocardiograms within 120 days after the AMI were available in 4 of 
the rGLP-1–treated patients, all of whom demonstrated sustained benefit (LVEF, 
36±3%), whereas 4 control patients showed LVEF remained at baseline (27±3%).14  
In-hospital mortality rate was 10% (1 of 10) in the rGLP-1–treated group and 
27% (3 of 11) in the control group. There were no cardiovascular deaths in the rGLP-1 
treated group, and 2 in the control group (18%): 1 from ventricular fibrillation and 1 from 
cardiogenic shock. Hospital length of stay was additionally significantly reduced in the 
rGLP-1 treated group compared with control subjects 6.1±1.3 versus 9.8±1.5 days, 
(p=0.02). 14 
Taken together, the authors14 concluded that the results show that the GLP-1 
treated group showed significant improvement of global LVEF, as well as regional 
functional recovery in the “peri-infarct” zone as expressed by decreased ventricular wall 
motion in the 72-hour post-operative period. Additionally, there was a trend toward 
decreased in-hospital mortality and decrease length of hospital stay.14 
Lonborg et al “Parent study” 
 13 
This paper described the results of a randomized, double-blinded, placebo-
controlled study15 performed at Copenhagen University Hospital in Rigshospitalet, 
Denmark and Aarhus University Hospital in Skejby, Denmark. This research investigated 
the cardioprotective effects of intravenous (IV) exenatide administered prior to 
reperfusion and continued after restoration of coronary blood flow in STEMI patients 
undergoing PCI. 172 patients met inclusion criteria and were eligible for the intention-to-
treat analysis. Patients were then randomized to either placebo or exenatide groups using 
a 1:1 computer generated sequence and numbered sealed envelopes with group 
assignment prior to angiography. Both operator and patient were blinded to the treatment 
before, during, and after the infusion. The placebo group received a saline infusion at the 
same rate as the treatment group infusion. Both treatment and placebo infusion contained 
human serum albumin. A 3-month cardiac magnetic resonance (CMR) was performed on 
117 patients. Of the total sample, 105 patients were available for the per-protocol study 
analysis of the primary endpoint: 85 patients in the treatment group and 87 the placebo 
group. This indicates that there was 39% loss to follow up for the per-protocol analysis of 
the primary endpoints due to contraindication, refusal, incapability, death, reinfarction, 
stent thrombosis, or temporary pacemaker. 
Exenatide infusion was commenced 15 minutes before the intervention and 
maintained for 6 hours after the procedure at 72mL/h (0.12ug/min) with a plasma goal of 
30-300 pmol/L. Mean plasma concentration of exenatide was 177±69 pmol/L. CMR was 
utilized to assess the myocardial area at risk (AAR) and final infarct size. The primary 
endpoint of this study was the myocardial salvage index measured by CMR after 3 
months. Secondary endpoints included final infarct size as assessed after 3 months, final 
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infarct size ratio (final infarct size (g)/AAR(g)), peak plasma level of troponin, LVEF by 
CMR at 3 months, and 30 day clinical events.  
Patients eligible for PCI were treated with ASA 300mg po (or 500mg IV), 
clopidogrel 600mg po, and 10,000u heparin IV. After randomization, angiography was 
performed to identify the location of the lesion. Direct stenting, thrombolectomy, and 
choice of stent were left to the discretion of the operator. Ischemic post conditioning, 
defined as 30 sec cycles of interruption of myocardial reperfusion with re-occlusion of 
vessel was not allowed.  Balloon angioplasty alone was limited to cases in which stent 
could not be deployed or was considered harmful.15   
The authors15 reported a significantly larger myocardial salvage index of 15% and 
a 23% smaller final infarct size ratio in the exenatide group (p=0.003). The AAR was not 
statistically different between treatment groups and peak troponin T levels were 
comparable between groups (6.4±4.9; 6.5±5.4ug/L). The authors15 reported the treatment 
effect was more pronounced with infarcts occurring in the distribution of the left anterior 
descending artery (LAD): 19% salvage index and 30% infarct size/AAR ratio.  Finally, 
the authors15 reported no difference between groups at 90 days LVEF by CMR.15 
Lonborg et al “Post-hoc analysis” 
This paper described the results of a post-hoc analysis16 of the above “parent 
study” that investigated system delay defined as time of first medical contact to balloon 
treatment on the effect of infarct size and myocardial salvage index in the setting of AMI 
for the exenatide group compared to the saline infusion group. This four-arm analysis 
allocated patients into exenatide or saline infusion groups, and divided the population by 
system delay of greater than or less than 132 minutes. In this study, 132 minutes was 
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defined by the authors16 as the median system delay for the patients. The inclusion and 
exclusion criteria differed from the “parent” study only in that patients with multivessel 
disease were not excluded from this study. There was significant loss to follow up 
consistent with the Lonborg et al “parent” study.15 However, inclusion of patients with 
multivessel disease yielded slightly different percentages of loss to follow up, 27% versus 
30% in treatment and control groups respectively due to the same reasons as outlined in 
the “parent” study.16 
The authors16 concluded in this post-hoc analysis that exenatide treatment 
decreased final infarct size 30% and increased myocardial slavage index 14% in STEMI 
patients with short system delay (<132 minutes). These findings were consistent with the 
previous study. Of interest, however, no effect of exenatide was observed in patients with 
long system delays (>132) minutes, and the authors16 concluded that this likely indicated 
an upper limit of ischemia duration for the cardioprotective effect of exenatide in AMI. 
Importantly, the inclusion or exclusion of patients with multivessel disease in a multi-
variable analysis did not affect the overall results.16  
 
DISCUSSION  
This review reveals a growing body of data supporting that GLP-1 or GLP-1 
receptor agonists have cardioprotective effects in the setting of AMI. These cardiac 
effects include improved LVEF, decreased infarct sizes, and increased myocardial 
salvage index. However, as of today, the cardioprotective capabilities of GLP-1 receptor 
agonists in the human model have not shown the same magnitude of outcomes as animal 
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models, and have yet to impact clinical practice in the management and treatment of AMI 
patients. 
Final Infarct Size, Myocardial Salvage Index, and Wall Motion 
One mechanism that may explain the cardioprotective effects of GLP-1 receptor 
agonists in AMI is the stimulation of glucose metabolism over fatty acid metabolism, 
which is a more efficient utilization of oxygen for ATP production in the ischemic 
myocardium.17 The shift from fatty acid metabolism to glucose metabolism by the 
cardiac myocytes is consistent with the insulinotropic effect of GLP-1 and the subsequent 
rise in plasma insulin following the administration of GLP-1 in both human and animal 
models.12,14, 18-20 Additionally, GLP-1 appears to have an anti-apoptotic effect 
independent of insulin on cardiac myocytes via cellular signaling11 and reduces the 
oxidative stress following reperfusion.12 Lonborg et al15 was able to show that infusion of 
exenatide in the setting of AMI increases myocardial salvage and decreases final infarct 
size. Interestingly, this effect was more pronounced with occlusions that occurred in the 
LAD. This is important to note because Stone et al21 found that patients with anterior 
infarcts (i.e. infarcts involving the LAD) had a disproportionate reduction in LVEF when 
compared to inferior infarcts. As a result, these patients had a higher incidence of heart 
failure, larger infarction sizes, and higher cardiac mortality over a 30-month period. 
Combining the data from these two studies15,21 leads to speculation that an anterior MI 
involving the LAD is statistically more severe and therefore GLP-1 has a more profound 
effect on infarct size and cardiac myocyte salvage. If this speculation is correct it would 
indicate a greater treatment effect in patients with more clinically significant disease.  
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Distracting from the possibility of a greater treatment effect of GLP-1 infusions 
with larger infarcts is the post-hoc analysis by Lonborg et al.16 This data is suggests a 
temporal upper limit to the efficacy of GLP-1 infusions in setting of AMI. Lonborg et al16 
reported an abolishment of benefit from GLP-1 infusions when time of first medical 
contact to reperfusion exceeds 132 minutes. The loss of cardioprotection in the extended 
system delay group is consistent with the findings of Gersh et al22 in that there is a 
“striking benefit” to interventions that occur in the first 2-3 hours after onset of ischemic 
symptoms. Therefore, it seems likely that the loss of cardioprotective benefit in the 
extended delay group is related more to the duration of time from symptom onset to 
definitive treatment, and less to do with the efficacy of the GLP-1 infusion itself.  Both of 
these studies16,22 add to the large body of literature noting AMI patients with longer 
ischemic times will likely have larger infarction areas, which results in fewer viable 
cardiac myocytes for salvage by reperfusion, thus patients will have increased morbidity 
and mortality post-MI. The absolute upper time limit of GLP-1 infusion has yet to be 
defined, but according to the Lonborg et al16 data appears to be less than 132 minutes. 
Another cardiac marker used to assess ventricular dysfunction in post-MI patients 
is ventricular wall motion. Nikolaidis et al14 reported that the regional wall motion score 
index (WMSI) over the area of ischemia was significantly decreased in the GLP-1 treated 
group, whereas no change was noted in the control group. This finding was replicated by 
Read et al19 in patients during dobutamine stress tests performed prior to elective PCI or 
CABG. Read et al19 reported that following a 30-minute GLP-1 infusion, patients 
demonstrated improved regional wall function, and the area of greatest benefit was seen 
in the region of the ischemic ventricular wall. Additionally, Nikolaidis et al14 reported 
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Global WMSI was also improved in GLP-1 treated patients, an effect that again was not 
observed the control group. Although Nikolaidis et al14 did not directly measure final 
infarct size or salvage index, one can postulate that decreased ventricular wall motion 
post-MI correlates with smaller infarct sizes and thus greater cardiac myocyte salvage, 
especially considering that the area of greatest benefit was observed in the distribution of 
the ischemic myocardium.  
Left Ventricular Ejection Fraction (LVEF) 
In the setting of AMI, GLP-1 infusions have been shown to improve LVEF in rat, 
porcine, and dog models;11, 12, 23 research in the human model has been less conclusive. 
Improvement in LVEF with GLP-1 infusion was noted in the Nikolaidis et al14 study. 
This study14 was able to show significant improvement of LVEF in Killip class II-IV 
patients, whereas no improvement was seen in the control group. Additionally, at 120 
days follow-up echocardiography exhibited sustained LVEF benefit in the treatment 
group.14 The Lonborg et al “parent” study15 was unable to show any benefit in LVEF in 
the treatment group at 90 days by CMR; however, the patient populations are not 
comparable between these studies.14,15 The Nikolaidis et al14 patients had a baseline mean 
LVEF of 29%, while the Lonborg et al15 patients LVEF was assessed only at 90 days and 
were clinically normal with a mean of 55%. Considering this, evaluation of LVEF at 90 
days in post-MI patients with normal LVEF is not likely to exhibit a statistically 
significant improvement between treatment and control groups. Additionally, LVEF was 
a secondary endpoint of the Lonborg et al15 study, and the study was not powered to 
evaluate LVEF. In a study that was powered to evaluate LVEF, Read et al19 reported 
GLP-1 infusion improved myocardial function by increasing LVEF during peak stress 
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and that effect was still evident 30 minutes into recovery.19 Interestingly, all patients in 
the Read et al19 study had clinically normal ejection fractions at rest. Based on these data 
sets,14,15,19 GLP-1 appears to  have a more pronounced effect on LVEF in patients with 
clinically significant ejection fractions, or if LVEF is assessed while patients are under 
cardiovascular stress.  
CMR versus Echocardiography 
          Echocardiography and CMR are the two most common and noninvasive modalities 
in use today to assess cardiac function. Although similar clinical endpoints are measured 
(i.e LVEF and ventricular wall motion) there are some discrepancies between the two 
modalities. In a moderately large prospective study comparing CMR versus 
echocardiography of post-MI patients in which patients served as their own control, 
Gardner et al24 reported that when compared to CMR, echocardiography underestimates 
left ventricular end diastolic volume (LVEDV) by an average of 69 ml, left ventricular 
end systolic volume (LVESV) by 35 ml, and stroke volume (SV) by 34 ml. Global LVEF 
correlated moderately well across the 2 modalities. However, echocardiography 
underestimated LVEF compared to CMR by 4% (CMR 51%, Echo 47%). Additionally, 
echocardiography underestimated wall motion scores (WMS) compared to CMR. In this 
study24 wall motion was completely normal in 32% of patients assessed by echo, 
compared to only 4% assessed by CMR, suggesting that CMR is more sensitive in 
distinguishing diseased from normal subjects. Another study19 reported an intra-observer 
variability in LVEF by echocardiography of 6% and an inter-observer variability of 7%, 
which creates an additional potential for inaccuracy.19 Applying these to the Nikolaidis et 
al14 and Lonborg et al15,16 data, suggests that the LVEF findings of the Nikolaidis et al14  
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data may be more robust than originally reported, while improved wall motion is 
potentially over-reported. Conversely, the Lonborg et al15 findings by CMR are likely 
very accurate due to the reproducibility and accuracy of CMR. 
Infusion Times and Plasma Concentration 
The optimal duration of infusion and plasma concentration of GLP-1 infusions 
has yet to quantified and with studies reporting conflicting data in regards to specific 
outcomes such as LVEF further research will be necessary. In this review, GLP-1 
infusion times were vastly different between the Nikolaidis et al14 and Lonborg et al 
studies15,16 (72 hours versus 6 hours respectively). These discrepancies of infusion 
duration may additionally help account for the lack of LVEF improvement at 90 days 
seen by Lonborg et al.15 A similar discrepancy of GLP-1 dose, duration, and conflicting 
findings regarding LVEF occurred in the setting of heart failure. Sokos et al25 was able to 
demonstrate improvement in LVEF in patients with New York Heart Association class 
II/IV heart failure after a 5-week infusion of GLP-1. Conversely, Halbirk et al,26 reported 
that a 48-hour infusion in non-diabetic patients with New York Heart Association class 
II/III heart failure had no effect on LVEF. What remains unclear at this time is whether 
there is a duration of GLP-1 infusion associated with sustained improvement in LVEF, 
and the Halbirk et al26 and Lonborg et al15,16 studies failed to achieve this threshold.  
Plasma concentrations were comparable between studies during infusion, 
Nikolaidis et al14 168+-21pmol/L and Lonborg et al15,16 177+-69 pmol/L. If one looks at 
clinically dosed GLP-1 receptor agonists in DM II, Byetta (exenatide) IR 10ug dosed 
twice daily achieves a mean plasma concentration of 50.4 pmol/L† with each dose,27 and 
Bydureon (exenatide) ER 2mg dosed once weekly achieves a similar mean plasma 
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concentration of 55.4 pmol/L, †28 but Bydureon achieves steady state plasma levels after 
just 2 weeks instead of 6 weeks as seen with Byetta.27,28 The minimum effective plasma 
concentration of exenatide is known to be 11.94 pmol/L† to effectively reduce fasting 
plasma glucose.28 However, minimum plasma concentration that still provides 
cardioprotection has yet to be explored. If the exenatide minimum effective plasma 
concentration for cardioprotection is near 50pmol/L, then exenatide and perhaps other 
GLP-1 receptor agonists could have great additional indications for use in the DM II 
population that carries a substantial elevated risk of adverse cardiac events. Again, the 
animal model has shown promise in this area. As an adjunct to intraoperative infusion of 
exenatide, pigs dosed with the standard human dose of exenatide IR 10ug twice daily for 
2 days following reperfusion exhibited a reduction in final infarct size and increased 
LVEF.12 Therefore, further studies are needed to quantify both the minimum effective 
cardioprotective plasma concentration, as well as the duration of infusion that will 
provide maximum benefit for AMI patients. 
In-Hospital Mortality and Hospital Length of Stay 
 The reduction of in-hospital mortality and length of hospital stay is of importance 
for patients and healthcare systems alike in any setting. The ability to reduce morbidity 
and mortality of AMI patients is the primary goal of intervention in this population. In a 
broader context, decreasing hospital length of stay additionally decreases the risk of 
nosocomial infection and other hospital-associated comorbid conditions, as well as the 
ever pertinent reduction of overall healthcare costs. Nikolaidis et al14 reported a trend 
toward decreased of in-hospital mortality in the treatment group (10% versus a 27% in 
the control group).  In a study29 investigating the predictive value of the Killip 
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classification in AMI patients undergoing PCI, DeGeare et al29 reported in-hospital 
mortality rates of 7% and 19% for Killip class II and Killip class III, respectively.29 This 
data is of interest because the patients in the Nikolaidis et al14 study were on average 
Killip class III patients and underwent the same procedure as the DeGeare et al29 patients. 
The Nikolaidis et al14 study reported a higher mortality of control patients than similar 
patients in the Degeare et al29 study, which may reflect that the Nikolaidis et al14 study 
included some Killip class IV patients, and had a significantly smaller sample size. 
However, mortality rates were significantly lower amongst comparable groups when 
treated with a GLP-1 infusion. Therefore, application of the findings of DeGeare et al29 to 
the trend reported by Nikolaidis et al14 is very suggestive of a significant reduction of in-
hospital mortality with the use of GLP-1 infusions in the treatment of AMI by PCI.  
 Similarly, Nikolaidis et al14 reported a decreased length of hospital stay in the 
treatment group compared to the control group (6.1 days versus 9.8 days respectively). 
This data is again comparable to the DeGeare et al29 data, which reported mean a hospital 
length of stay of 8.2 days in Killip class II patients and 10.8 days for Killip class III. The 
similarity of length of stay between the control group and the DeGeare et al29 patients 
lends credence to the 3 day reduction of hospital stay observed in the treatment group of 
Nikolaidis et al14 study. Taken together, the results of these studies14,29 suggest that GLP-
1 infusion in the setting of AMI appears to have great potential for the reduction of 
morbidity and mortality, as well as reducing the duration of hospital stay.  
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LIMITATIONS OF STUDIES 
The Nikolaidis et al study14 is limited most severely by design and sample size. 
The study was a non-randomized pilot study, but pretest analysis reveals that treatment 
and placebo groups were very similar, which decreases the risk of selection bias. The trial 
additionally would have been strengthened if it were placebo-controlled and double-
blinded. Instead, only echocardiogram readers were blinded. The extremely small sample 
size (n=21) additionally leads to many issues especially with precision.14 
The Lonborg et al “parent study”15 is significantly limited by the loss to follow up 
of 39% in the per-protocol analysis. There were 31 (36%) patients lost to follow up 
treatment group and 36 (41%) patients in control group. Additionally, the opening of 
numbered envelopes may have created a potential for selection bias, as the authors were 
aware of which infusion the patients would receive immediately following informed 
consent, but there is no discussion as to how the operators and patients remained blinded 
to the treatment. Finally, there also is no mention of visual characteristics of treatment 
infusion versus placebo infusion other than the rates of the infusions were the same, and 
both infusions contained human serum albumin, which leads to potential issues with 
concealment15 
The Lonborg et al post hoc analysis16 was inherently limited by significant loss to 
follow up in the per protocol analysis. However, inclusion of patients with multivessel 
disease yielded slightly lower percentages of loss to follow up, 27% versus 30% in both 
the treatment and control groups respectively.16 Additionally, there is significant potential 
for selection bias in that the exact system delay cut-off time unknown, however the 
authors16 use of a median minimizes the risk of selection bias when a population is 
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broken into subgroups.16 
 
RECOMMENDATIONS 
More research needs to be conducted on GLP-1 infusions in the setting of AMI. 
Currently underway are two large FDA mandated trials:30 LEADER31 and EXSCEL.32 
Unfortunately, these two trials31,32 are not expected to report data until 2016 or later.  The 
LEADER trial31 is a multi-national, multi-centered, randomized, double-blinded, placebo 
controlled study of 9341 patients with DM II. The LEADER trial31 is examining the 
effect of liraglutide 1.8mg on the primary outcomes of cardiovascular death, non-fatal 
MI, and non-fatal stroke over five years. The EXSCEL trial32 is a randomized, double-
blinded, placebo controlled study whose primary outcome is the first confirmed cardiac 
event of 9500 patients with DM II over 5.5 years. Additionally underway is the EXAMI 
trial, 33 a multicenter, prospective, randomized, placebo controlled trial underway 
investigating a 72-hour exenatide infusion following AMI and PCI. This study33 will use 
both MRI and echocardiography to assess regional cardiac function. These three studies 
will hopefully provide answers to many of the questions raised by previous investigations 
into the cardioprotective effects of GLP-1 receptor agonists. 
 
CONCLUSION 
The studies14-16 reviewed in this paper provide very clinically relevant and 
encouraging results for a future role of GLP-1/GLP-1 receptor agonists in patients 
suffering an AMI. Longer duration GLP-1 infusions have been shown to improve LVEF, 
a finding that was more pronounced in patients with clinically severe disease,14 or in 
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patients under cardiovascular stress.18 Infusions of exenatide in the setting of AMI 
increases myocardial salvage and decreases final infarct size with more profound findings 
involving infarcts over the distribution of the LAD.15 Anterior MIs involving the LAD 
have been shown to be clinically more severe,21 which gives rise to the potential that 
GLP-1 infusions have a more profound effect on larger infarcts since there are likely 
more cardiac myocytes available for salvage. However, there does appear to be an 
absolute upper limit to the timing of GLP-1 administration, and at this time, this limit is 
less than 132 minutes from the time of first medical contact.16 This finding is consistent 
with current understanding that the shorter the delay in treatment of AMI yields a greater 
reduction in morbidity and mortality.22 GLP-1 infusions also appear to decrease 
morbidity and mortality in AMI patients themselves, as evidenced by the reduction of in-
hospital mortality and length of hospital stay.14At this time, GLP-1 infusions remain as a 
potential therapy for cardioprotection and reduction of morbidity and mortality in setting 
of AMI. We await the results of the ongoing LEADER, EXSCEL, and EXAMI studies 
with great anticipation for the potential implications on future clinical practice in the 
management of DM II and AMI. 
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TABLE 1 
Characteristics of Studies and Findings 
Author: Nikolaidis et al Lonborg et al 
“Parent” 
Lonborg et al 
“system delay” 
Study type Non-Randomized 
Pilot Study 
RCT Post hoc 
Analysis 
# of Patients             21          172        148 
Infusion Time 
 
 
 
and 
 
 
 
 
Plasma Conc. 
72 hour post-op 
infusion rGLP-1 
@1.5pmol/kg/min.  
 
 
 
 
 
 
Plasma GLP-1 
levels: 168+-
21pmol/L 
15 min pre-op 
and 6 hours  
post-op @ 
72mL/h  
0.12ug/kg/min 
for 15min, then 
.043ug/kg/min 
for 6 hours. 
 
Plasma conc. 
exenatide 
177+-69 
pmol/L† 
 
15 min pre-op 
and 6 hours  
post-op @ 
72mL/h 
0.12ug/kg/min 
for 15min, then 
.043ug/kg/min 
for 6 hours. 
 
Plasma conc. 
exenatide 
177+-69 
pmol/L† 
 
Ratio Final 
Infarct Size 
(AAR/Infarct 
Size) 
 
 
 
Regional Wall 
Motion 
 
         N/A 
 
 
 
 
 
Decreased  
-21+-2% 
(P<0.001) 
Decreased 23%  <132 min: 
Decreased 30% 
 
>132 min: No 
Difference  
Myocardial 
Salvage Index 
         N/A Increased 15% <132min: 
increased 14% 
 
 
 
 
 
 
 
LVEF %  
GLP-1: (29+-2% 
to 39+-2%)  
 
Control: 
 (28+-2% to 
29+-2%) 
(P<0.01) 
  
Post infusion: 
GLP-1: (36+-3%) 
Control: (27+-3%) 
at 120 days. 
 
 
GLP-1:(55+-
9%) 
 
Control: 
(58+-8%) 
(P=0.13) 
At 90 days 
GLP-1:(53+-
6%) 
 
Control: 
(55+-7%) 
(P=0.41) at 
90 days  
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Table 2 
1. Killip Classification of Acute Myocardial infarction34 
Class I No evidence of heart failure 
Class II Physical exam findings consistent with mild to 
moderate heart failure (S3 gallop, Lung rales half 
way up posterior lung fields, or jugular venous 
distension 
Class III Overt pulmonary edema 
Class IV Cardiogenic shock 
 † Exenatide plasma concentrations were calculated by the author using molecular weight 
of extendin-4 (exenatide) = 4186.61.35,36 
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Table 3 GRADE Quality Assessment 
 
 
 
aNo Randomization and single center sample in the Nikolaidis et al3 study creates significant potential for selection bias, however, pretest analysis revealed similarity 
between groups. Additionally, echocardiogram readers were blinded to reduce risk of detection bias. There was also significant loss to follow up in the Nikolaidis et al 
study1 and the Lonborg et al studies1,2. 
bWide confidence intervals and small sample sizes. 
 
Lonborg studies were funded by Novo Nordisk Foundation, which markets the Victoza (liraglutide) another GLP-1 agonist and competitor to Byetta (exenatide)  
 
 
 
 
 
 
 
 
Quality Assessment Summary of Findings 
 Downgrade Criteria  Number of Patients 
Quality Importance No. of 
Studies Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely Study 
Treatment 
(total) 
Placebo or 
no treatment 
(total) 
Myocardial Salvage Index 
2 
1 RCT 
1 Post-hoc 
analysis 
No serious 
limitations 
No serious 
indirectness 
 Serious 
imprecisionb 
No serious 
inconsistencies 
No Bias 
likely 
  Lonborg et al15 54 51 
Low Important  Lonborg et al16 
 
38,39 36,35 
LVEF% 
3 
1RCT 
1 Post hoc 
analysis 
1 non-
randomized pilot 
study 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No Bias 
likely 
Lonborg et al15 54 51 
Low Important 
Lonborg et al16 38,39 36,35 
Nikolaidis et al14 10 11 
Final infarct size/Area At Risk (AAR) & Regional wall motion 
3 
1RCT 
1 Post hoc 
analysis 
1 non-
randomized pilot 
study 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
No serious 
inconsistencies 
No Bias 
likely 
Lonborg et al15 54 51 
Low Important 
Lonborg et al16 38,39 36,35 
Nikolaidis et al14 10 11 
